BlueCrest Capital Management’s Albany Molecular Research Inc AMRI Stock Holding History

BlueCrest Capital Management’s Portfolio AMRI Stock Details AMRI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-11,061	Closed	-$220K	–	1281
2015 Q4	$220K	Buy	+11,061	New	+$210K	0.01%	821

Other funds holding AMRI

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

OWP

Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

VNIM

Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

ACM

American Capital Management New York $1.86B AUM 20.23% 1-Year Est. Return

PIP

Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlueCrest Capital Management's AMRI Position: Q1 2016 in Review

BlueCrest Capital Management sold out of Albany Molecular Research Inc (AMRI) in Q1 2016, closing a stake of 11,061 shares — an estimated $220K sold.

BlueCrest Capital Management first reported a position in AMRI in Q4 2015 and held it in 1 quarter. The position peaked at $220K in Q4 2015. 141 funds tracked by Wall St. Rank hold AMRI as of Q1 2016.

BlueCrest Capital Management reported no remaining Albany Molecular Research Inc position as of Q1 2016 after selling out during the quarter.
BlueCrest Capital Management sold 11,061 Albany Molecular Research Inc shares in Q1 2016, an estimated $220K.
BlueCrest Capital Management first reported a position in Albany Molecular Research Inc in Q4 2015 and held it in 1 quarter.
BlueCrest Capital Management's Albany Molecular Research Inc position peaked at $220K in Q4 2015.
141 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q1 2016.

Based on BlueCrest Capital Management's 13F filing for Q1 2016, filed 3 May 2016.